Claudia L Côté1, Alexandra M Yip1, Jeffrey B MacLeod1, Bill O'Reilly1, Joshua Murray1, Maral Ouzounian1, Craig D Brown1, Rand Forgie1, Marc P Pelletier1, Ansar Hassan1. 1. From Dalhousie Medicine, New Brunswick, Saint John, NB (Côté); Cardiovascular Research, New Brunswick Heart Center, Saint John Regional Hospital, Saint John, NB (Yip, MacLeod, Forgie, Pelletier, Hassan); Clinical Perfusion Services, Saint John Regional Hospital, Saint John, NB (O'Reilly); the Cardiovascular Data Management Centre, Hospital for Sick Children, University of Toronto, Toronto, Ont. (Murray); and the Toronto General Hospital, Toronto, Ont. (Ouzounian).
Abstract
BACKGROUND: Evidence regarding the safety and efficacy of intraoperative cell salvage (ICS) in transfusion reduction during cardiac surgery remains conflicting. We sought to evaluate the impact of routine ICS on outcomes following cardiac surgery. METHODS: We conducted a retrospective analysis of patients who underwent nonemergent, first-time cardiac surgery 18 months before and 18 months after the implementation of routine ICS. Perioperative transfusion rates, postoperative bleeding, clinical and hematological outcomes, and overall cost were examined. We used multivariable logistic regression modelling to determine the risk-adjusted effect of ICS on likelihood of perioperative transfusion. RESULTS: A total of 389 patients formed the final study population (186 undergoing ICS and 203 controls). Patients undergoing ICS had significantly lower perioperative transfusion rates of packed red blood cells (pRBCs; 33.9% v. 45.3% p = 0.021), coagulation products (16.7% v. 32.5% p < 0.001) and any blood product (38.2% v. 52.7%, p = 0.004). Patients receiving ICS had decreased mediastinal drainage at 12 h (mean 320 [range 230-550] mL v. mean 400 [range 260-690] mL, p = 0.011) and increased postoperative hemoglobin (mean 104.7 ± 13.2 g/L v. 95.0 ± 11.9 g/L, p < 0.001). Following adjustment for other baseline and intraoperative covariates, ICS emerged as an independent predictor of lower perioperative transfusion rates of pRBCs (odds ratio [OR] 0.52, 95% confidence interval [CI] 0.31-0.87), coagulation products (OR 0.41, 95% CI 0.24-0.71) and any blood product (OR 0.47, 95% CI 0.29-0.77). Additionally, ICS was associated with a cost benefit of $116 per patient. CONCLUSION: Intraoperative cell salvage could represent a clinically cost-effective way of reducing transfusion rates in patients undergoing cardiac surgery. Further research on systematic ICS is required before recommending it for routine use.
BACKGROUND: Evidence regarding the safety and efficacy of intraoperative cell salvage (ICS) in transfusion reduction during cardiac surgery remains conflicting. We sought to evaluate the impact of routine ICS on outcomes following cardiac surgery. METHODS: We conducted a retrospective analysis of patients who underwent nonemergent, first-time cardiac surgery 18 months before and 18 months after the implementation of routine ICS. Perioperative transfusion rates, postoperative bleeding, clinical and hematological outcomes, and overall cost were examined. We used multivariable logistic regression modelling to determine the risk-adjusted effect of ICS on likelihood of perioperative transfusion. RESULTS: A total of 389 patients formed the final study population (186 undergoing ICS and 203 controls). Patients undergoing ICS had significantly lower perioperative transfusion rates of packed red blood cells (pRBCs; 33.9% v. 45.3% p = 0.021), coagulation products (16.7% v. 32.5% p < 0.001) and any blood product (38.2% v. 52.7%, p = 0.004). Patients receiving ICS had decreased mediastinal drainage at 12 h (mean 320 [range 230-550] mL v. mean 400 [range 260-690] mL, p = 0.011) and increased postoperative hemoglobin (mean 104.7 ± 13.2 g/L v. 95.0 ± 11.9 g/L, p < 0.001). Following adjustment for other baseline and intraoperative covariates, ICS emerged as an independent predictor of lower perioperative transfusion rates of pRBCs (odds ratio [OR] 0.52, 95% confidence interval [CI] 0.31-0.87), coagulation products (OR 0.41, 95% CI 0.24-0.71) and any blood product (OR 0.47, 95% CI 0.29-0.77). Additionally, ICS was associated with a cost benefit of $116 per patient. CONCLUSION: Intraoperative cell salvage could represent a clinically cost-effective way of reducing transfusion rates in patients undergoing cardiac surgery. Further research on systematic ICS is required before recommending it for routine use.
Authors: Aditya K Kaza; Jeffrey T Cope; Steven M Fiser; Stewart M Long; John A Kern; Irving L Kron; Curtis G Tribble Journal: Ann Thorac Surg Date: 2003-02 Impact factor: 4.330
Authors: Paul A Carless; David A Henry; Annette J Moxey; Dianne O'Connell; Tamara Brown; Dean A Fergusson Journal: Cochrane Database Syst Rev Date: 2010-04-14
Authors: Gabriel Loor; Jeevanantham Rajeswaran; Liang Li; Joseph F Sabik; Eugene H Blackstone; Keith R McCrae; Colleen G Koch Journal: J Thorac Cardiovasc Surg Date: 2013-08-30 Impact factor: 5.209
Authors: G Scrascia; C Rotunno; D Nanna; R Rociola; P Guida; G Rubino; L de Luca Tupputi Schinosa; D Paparella Journal: Perfusion Date: 2012-03-22 Impact factor: 1.972
Authors: M J Dalrymple-Hay; L Pack; C D Deakin; S Shephard; S K Ohri; M P Haw; S A Livesey; J L Monro Journal: Eur J Cardiothorac Surg Date: 1999-06 Impact factor: 4.191
Authors: George Djaiani; Ludwik Fedorko; Michael A Borger; Robin Green; Jo Carroll; Michael Marcon; Jacek Karski Journal: Circulation Date: 2007-10-08 Impact factor: 29.690